ZA201101739B - Compounds for the treatment of hepatitis c - Google Patents

Compounds for the treatment of hepatitis c

Info

Publication number
ZA201101739B
ZA201101739B ZA2011/01739A ZA201101739A ZA201101739B ZA 201101739 B ZA201101739 B ZA 201101739B ZA 2011/01739 A ZA2011/01739 A ZA 2011/01739A ZA 201101739 A ZA201101739 A ZA 201101739A ZA 201101739 B ZA201101739 B ZA 201101739B
Authority
ZA
South Africa
Prior art keywords
hepatitis
compounds
treatment
Prior art date
Application number
ZA2011/01739A
Other languages
English (en)
Inventor
Kap-Sun Yeung
John A Bender
Katharine A Grant-Young
Piyasena Hewawasam
Andrew Nickel
Kyle E Parcella
Brett R Beno
Ying Han
John F Kadow
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41226922&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ZA201101739(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of ZA201101739B publication Critical patent/ZA201101739B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/84—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Furan Compounds (AREA)
  • Peptides Or Proteins (AREA)
ZA2011/01739A 2008-09-11 2011-03-01 Compounds for the treatment of hepatitis c ZA201101739B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9600508P 2008-09-11 2008-09-11
PCT/US2009/056166 WO2010030592A1 (en) 2008-09-11 2009-09-08 Compounds for the treatment of hepatitis c

Publications (1)

Publication Number Publication Date
ZA201101739B true ZA201101739B (en) 2012-08-29

Family

ID=41226922

Family Applications (2)

Application Number Title Priority Date Filing Date
ZA2011/01739A ZA201101739B (en) 2008-09-11 2011-03-01 Compounds for the treatment of hepatitis c
ZA2011/05720A ZA201105720B (en) 2008-09-11 2011-08-03 Compounds for the treatment of hepatitis c

Family Applications After (1)

Application Number Title Priority Date Filing Date
ZA2011/05720A ZA201105720B (en) 2008-09-11 2011-08-03 Compounds for the treatment of hepatitis c

Country Status (19)

Country Link
US (1) US8048887B2 (enExample)
EP (1) EP2326633B1 (enExample)
JP (1) JP5685191B2 (enExample)
KR (1) KR20110059875A (enExample)
CN (1) CN102209717B (enExample)
AR (1) AR073740A1 (enExample)
AU (1) AU2009291966B2 (enExample)
BR (1) BRPI0918174A2 (enExample)
CA (1) CA2736988A1 (enExample)
CL (2) CL2011000527A1 (enExample)
CO (1) CO6382110A2 (enExample)
EA (1) EA019185B1 (enExample)
IL (1) IL211509A0 (enExample)
MX (1) MX2011002410A (enExample)
NZ (1) NZ591172A (enExample)
PE (1) PE20110806A1 (enExample)
TW (2) TW201124403A (enExample)
WO (1) WO2010030592A1 (enExample)
ZA (2) ZA201101739B (enExample)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7994171B2 (en) * 2008-09-11 2011-08-09 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US8198449B2 (en) * 2008-09-11 2012-06-12 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2361242B1 (en) 2008-10-17 2018-08-01 Oryzon Genomics, S.A. Oxidase inhibitors and their use
JP2012507539A (ja) * 2008-10-30 2012-03-29 メルク・シャープ・エンド・ドーム・コーポレイション ２，５−二置換フェニルカルボキサミド・オレキシン受容体アンタゴニスト
WO2010084160A1 (en) 2009-01-21 2010-07-29 Oryzon Genomics S.A. Phenylcyclopropylamine derivatives and their medical use
CN102574778B (zh) * 2009-06-22 2015-01-07 弗·哈夫曼-拉罗切有限公司 新的联苯基和苯基-吡啶酰胺类化合物
RU2602814C2 (ru) 2009-09-25 2016-11-20 Оризон Дженомикс С.А. Лизинспецифические ингибиторы деметилазы-1 и их применение
WO2011042217A1 (en) 2009-10-09 2011-04-14 Oryzon Genomics S.A. Substituted heteroaryl- and aryl- cyclopropylamine acetamides and their use
WO2011106574A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibitors for antiviral use
WO2011106573A2 (en) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with hepadnaviridae
US8324212B2 (en) * 2010-02-25 2012-12-04 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
TW201136919A (en) * 2010-03-02 2011-11-01 Merck Sharp & Amp Dohme Corp Inhibitors of hepatitis C virus NS5B polymerase
US8354410B2 (en) * 2010-03-11 2013-01-15 Bristol-Meyers Squibb Company Compounds for the treatment of hepatitis C
CN102906080A (zh) * 2010-03-11 2013-01-30 百时美施贵宝公司 治疗丙型肝炎的化合物
AU2011244325B2 (en) 2010-04-19 2015-12-17 Oryzon Genomics S.A. Lysine specific demethylase-1 inhibitors and their use
AR082453A1 (es) 2010-04-21 2012-12-12 Novartis Ag Compuestos de furopiridina, composiciones farmaceuticas que los contienen y usos de los mismos
WO2011140333A1 (en) 2010-05-07 2011-11-10 The Board Of Trustees Of The Leland Stanford Junior University Identification of stabilizers of multimeric proteins
US8445497B2 (en) 2010-06-30 2013-05-21 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2012013727A1 (en) 2010-07-29 2012-02-02 Oryzon Genomics S.A. Cyclopropylamine derivatives useful as lsd1 inhibitors
ME03085B (me) 2010-07-29 2019-01-20 Oryzon Genomics Sa Demetilaza inhibitori lsd1 zasnovani na arilciklopropilaminu i njihova medicinska primjena
EP2963034A1 (en) 2010-08-26 2016-01-06 RFS Pharma, LLC. Potent and selective inhibitors of hepatitis c virus
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012058125A1 (en) 2010-10-26 2012-05-03 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
WO2012072713A2 (en) * 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Lysine demethylase inhibitors for diseases and disorders associated with flaviviridae
US8507683B2 (en) * 2010-12-09 2013-08-13 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
JP5918264B2 (ja) * 2010-12-22 2016-05-18 アッヴィ・インコーポレイテッド Ｃ型肝炎阻害剤およびその使用
EP3981395A1 (en) 2011-02-08 2022-04-13 Oryzon Genomics, S.A. Lysine demethylase inhibitors for myeloproliferative disorders
WO2013033901A1 (en) 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases
WO2013033900A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases
WO2013033899A1 (en) * 2011-09-08 2013-03-14 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases
KR102079406B1 (ko) 2011-10-20 2020-02-19 오리존 지노믹스 에스.에이. Lsd1 억제제로서의 (헤테로)아릴 사이클로프로필아민 화합물
WO2013057320A1 (en) 2011-10-20 2013-04-25 Oryzon Genomics, S.A. (hetero)aryl cyclopropylamine compounds as lsd1 inhibitors
US9303020B2 (en) 2012-02-08 2016-04-05 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
EP2831066B1 (en) 2012-03-27 2016-10-05 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
WO2013163466A1 (en) * 2012-04-25 2013-10-31 Presidio Pharmaceuticals, Inc. Inhibitors of hepatitis c virus
US9169214B2 (en) 2012-12-21 2015-10-27 The Board Of Trustees Of The Leland Stanford Junior University Compounds and compositions that bind and stabilize transthyretin and their use for inhibiting transthyretin amyloidosis and protein-protein interactions
EP2943496B1 (en) * 2013-01-10 2017-09-06 Bristol-Myers Squibb Company Macrocyclic benzofuran and azabenzofuran compounds for the treatment of hepatitis c
WO2014121416A1 (en) 2013-02-07 2014-08-14 Merck Sharp & Dohme Corp. Tetracyclic heterocycle compounds and methods of use thereof for the treatment of hepatitis c
US8962651B2 (en) 2013-03-13 2015-02-24 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
US9738653B2 (en) 2013-03-14 2017-08-22 Bristol-Myers Squibb Company Fused furans for the treatment of hepatitis C
WO2014205593A1 (en) 2013-06-24 2014-12-31 Merck Sharp & Dohme Corp. Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases
US9556162B2 (en) 2013-12-13 2017-01-31 Bristol-Myers Squibb Company Compound for the treatment of hepatitis C
US9920036B2 (en) * 2014-03-21 2018-03-20 Bristol-Myers Squibb Company Cyanoamino (aza)benzofuran compounds for the treatment of hepatitis C
TW201620914A (zh) * 2014-03-21 2016-06-16 必治妥美雅史谷比公司 含有氰基之氮雜苯并呋喃化合物用於治療ｃ型肝炎
JP6543342B2 (ja) 2014-08-14 2019-07-10 アルハマドシャー，マモウン，エム． 血清半減期を延長するための、調節可能リンカーを介した薬学的活性剤とトランスサイレチンリガンドのコンジュゲーション
WO2016133972A1 (en) * 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Substituted benzofuran compounds for the treatment of hepatitis c
US10125137B2 (en) 2015-02-19 2018-11-13 Bristol-Myers Squibb Company Benzofurans substituted with bicyclic secondary benzamide as HCV inhibitors
US10131645B2 (en) 2015-02-19 2018-11-20 Bristol-Myers Squibb Company Benzofurans substituted with primary benzamide as HCV inhibitors
WO2016133963A1 (en) * 2015-02-19 2016-08-25 Bristol-Myers Squibb Company Benzofurans substituted with secondary benzamide as hcv inhibitors
US10150747B2 (en) 2015-02-23 2018-12-11 Bristol-Myers Squibb Company Compounds for the treatment of hepatitis C
WO2017165233A1 (en) * 2016-03-21 2017-09-28 Bristol-Myers Squibb Company Benzofuran derivatives for the treatment of hepatitis c
MX2021015220A (es) 2017-02-17 2022-12-01 Eidos Therapeutics Inc Procesos para preparar ácido 3-(3-(3,5-dimetil-1h-pirazol-4-il)pro poxi)-4- 5-fluorobenzoico (ag-10), sus compuestos intermedios, y sales del mismo.
KR102512548B1 (ko) 2017-12-22 2023-03-22 삼성디스플레이 주식회사 유기 전계 발광 소자 및 유기 전계 발광 소자용 함질소 화합물
UA130053C2 (uk) 2018-03-23 2025-10-29 Ейдос Терапьютікс, Інк. Спосіб лікування транстиретинового амілоїдозу із застосуванням ag10
CN112804998A (zh) 2018-08-17 2021-05-14 文涵治疗有限公司 Ag10的制剂
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
WO2021008512A1 (zh) * 2019-07-18 2021-01-21 石药集团中奇制药技术（石家庄）有限公司 作为nmt抑制剂的化合物及其应用
US20250214977A1 (en) * 2024-01-03 2025-07-03 Kymera Therapeutics, Inc. Stat6 inhibitors and uses thereof

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57123181A (en) 1981-01-23 1982-07-31 Mitsubishi Paper Mills Ltd Preparation of pyrazolo (1,5-a) pyridine derivative
PE20020506A1 (es) 2000-08-22 2002-07-09 Glaxo Group Ltd Derivados de pirazol fusionados como inhibidores de la proteina cinasa
US20050107400A1 (en) 2001-03-30 2005-05-19 Boyd Leslie F. Use of pyrazolopyridines as therapeutic compounds
EP1581207A4 (en) * 2002-11-01 2007-07-25 Viropharma Inc BENZOFURAN COMPOUNDS, COMPOSITIONS AND METHODS OF TREATING AND PROPHYLAXIS OF VIRAL INFECTIONS WITH HEPATITIS C AND RELATED ILLNESSES
US7868037B2 (en) * 2004-07-14 2011-01-11 Ptc Therapeutics, Inc. Methods for treating hepatitis C
TW200815384A (en) * 2006-08-25 2008-04-01 Viropharma Inc Combination therapy method for treating hepatitis C virus infection and pharmaceutical compositions for use therein
CN101687789A (zh) * 2007-02-12 2010-03-31 因特蒙公司 C型肝炎病毒复制的新颖抑制剂
GB0707000D0 (en) 2007-04-12 2007-05-30 Istituto Di Ricerche D Biolog Antiviral agents
AU2009214194B2 (en) * 2008-02-14 2012-05-17 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
WO2009137493A1 (en) 2008-05-05 2009-11-12 Wyeth 2-substituted benzofuran compounds to treat infection with hepatitis c virus
WO2009137500A1 (en) 2008-05-05 2009-11-12 Wyeth 6-substituted benzofuran compounds to treat infection with hepatitis c virus

Also Published As

Publication number Publication date
TW201124403A (en) 2011-07-16
BRPI0918174A2 (pt) 2019-10-01
JP5685191B2 (ja) 2015-03-18
IL211509A0 (en) 2011-07-31
CO6382110A2 (es) 2012-02-15
WO2010030592A1 (en) 2010-03-18
JP2012502101A (ja) 2012-01-26
ZA201105720B (en) 2012-08-29
MX2011002410A (es) 2011-04-05
EP2326633A1 (en) 2011-06-01
US8048887B2 (en) 2011-11-01
CL2011000527A1 (es) 2011-08-12
EP2326633B1 (en) 2015-12-16
KR20110059875A (ko) 2011-06-07
AR073740A1 (es) 2010-12-01
TW201014836A (en) 2010-04-16
PE20110806A1 (es) 2011-10-31
EA019185B1 (ru) 2014-01-30
AU2009291966B2 (en) 2014-08-28
CL2011001224A1 (es) 2011-09-16
EA201100390A1 (ru) 2011-10-31
CN102209717B (zh) 2015-02-18
NZ591172A (en) 2012-12-21
CA2736988A1 (en) 2010-03-18
US20100093694A1 (en) 2010-04-15
CN102209717A (zh) 2011-10-05
AU2009291966A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
ZA201101739B (en) Compounds for the treatment of hepatitis c
ZA200906129B (en) Compounds for the treatment of hepatitis c
IL207570A0 (en) Oxadiazoanthracene compounds for the treatment of diabetes
LT2303021T (lt) Junginiai, skirti vėžio gydymui
SI2209784T1 (sl) Spojine za zdravljenje hepatitisa C
ZA201000923B (en) Compounds for the treatment of hepatitis c
EP2343066A4 (en) THERAPEUTIC AGENT FOR HEPATITIS C
ZA200902374B (en) Compositions useful for the treatment of diabetes
EP2331123A4 (en) COMPOSITIONS AND METHODS FOR TREATING HEPATITIS C
PL2151428T3 (pl) Nowy sposób syntezy agomelatyny
IL207520A0 (en) Carboxamide-heteroaryl derivatives for the treatment of diabetes
EP2323979A4 (en) TREATMENT OR PREVENTION OF HEPATITIS C WITH IMMUNOMODULATOR COMPOUNDS
IL211189A0 (en) Compounds for the treatment of peripheral neuropathies
EG26332A (en) Process for the preparation of benzonoprons
IL243809A0 (en) Process for the production of γ-ketosulfide compound and γ-ketosulfide compounds
IL210066A0 (en) Novel ortho-aminoanilides for the treatment of cancer
PT2151429E (pt) Novo processo de síntese da agomelatina
PL2896614T3 (pl) Sposoby i związki do wytwarzania normorfinanów
IL211382A0 (en) Process for the preparation of ethanedinitrile
HK1152310A (en) Compounds for the treatment of hepatitis c
TH0801003323A (th) สารประกอบสำหรับการบำบัดโรคตับอักเสบ c
GB0717139D0 (en) Treatment of hepatitis C
GB0816217D0 (en) Treatment of hepatitis C
HK1133007A (zh) 治療丙型肝炎的化合物
HK1138846A (en) Compounds for the treatment of hepatitis c